Navidea Biopharmaceuticals Inc (NAVB)

[DADDY FAT SAXX]

NEWS

Neoprobe to Present at Needham and Company’s 10th Annual Healthcare Conference

Source:biowire

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Dr. Mark Pykett, Neoprobe’s Executive Vice President and Chief Development Officer, will deliver a presentation to institutional investors at the Needham & Company’s 10th Annual Healthcare Conference at 2:40 PM on Tuesday, April 5, 2011 at The New York Palace Hotel. The Needham & Company’s 10th Annual Healthcare Conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both public and private companies in the biotechnology, specialty pharmaceuticals, medical technology and diagnostics sectors.

Investors and the public are invited to listen to a live webcast of Dr. Pykett’s presentation at http://www.wsw.com/webcast/needham44/neop.ob/. This link can also be found on the Investor Relations page of the Company’s website at www.neoprobe.com. An archived edition of the presentation will be available the next day.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing oncology patient care and improving patient benefit. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScanTM CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com